Skip to Content
Merck
All Photos(1)

Documents

20362

Supelco

ORBO™ 92 Carboxen® 564 (20/45), 160/80 mg

W,F,F separators, O.D. × L 6 mm × 75 mm, pkg of 25 ea, for analyte group Vinyl acetate

Synonym(s):

ORBO™ Carboxen-564 Tube

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

EC Number:
231-153-3
UNSPSC Code:
47131900

material

W,F,F separators

Agency

NIOSH 1453
OSHA 51

product line

ORBO™

composition

Bed A, 160 mg
Bed B, 80 mg

packaging

pkg of 25 ea

manufacturer/tradename

ORBO™ 92

technique(s)

active air sampling: suitable

O.D. × L

6 mm × 75 mm

matrix

Carboxen® 564 Carbon Molecular Sieve (CMS)

application(s)

air monitoring
environmental
industrial hygiene

compatibility

for analyte group Vinyl acetate

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

  • ORBO™ 92 Carboxen® 564 (20/45), 160/80 mg solvent desorption tube is designed for gas and vapor sampling.
  • It contains two beds of the same selective adsorbent separated by glass wool or foam.
  • Dual-layer or two-bed construction of the tube allows for any sample breakthrough to be captured in the smaller back-up bed.

Legal Information

Carboxen is a registered trademark of Merck KGaA, Darmstadt, Germany
ORBO is a trademark of Sigma-Aldrich Co. LLC

Storage Class Code

11 - Combustible Solids

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Anne Ørbo et al.
The Journal of steroid biochemistry and molecular biology, 113(1-2), 139-149 (2009-01-14)
Patients with endometrial hyperplasia representing preliminary stages of endometrial cancer have shown to respond to therapy in 100% of the cases when treated with levonorgestrel-impregnated intrauterine device. Anti-proliferative effect has also been reported after application of an anti-progestin impregnated intrauterine
A Orbo et al.
International journal of oncology, 5(3), 619-625 (1994-09-01)
About 50% of the cases with invasive carcinoma of the uterine cervix occurs before menopause. Cyclic changes of sex steroids may therefore interfere with the ratio between extracellular levels of cGMP and cAMP (cGMP(ex)/cAMP(ex)). This ratio has been proposed as
H Stalsberg et al.
Virchows Archiv. A, Pathological anatomy and histopathology, 414(5), 415-422 (1989-01-01)
The autopsies of 12 victims from two snow avalanches in North-Norway are reported. Supportive evidence from non-autopsied and surviving victims is included. Consistent autopsy findings were prominent lung oedema, moderate cerebral oedema, extreme contraction of the left ventricle, petechiae in
A Ørbo et al.
BJOG : an international journal of obstetrics and gynaecology, 123(9), 1512-1519 (2015-12-03)
To investigate relapse rates after the successful treatment of patients with non-atypical endometrial hyperplasia who were randomised to either a levonorgestrel-impregnated intrauterine system (LNG-IUS; Mirena(®) ) or two regimens of oral medroxyprogesterone acetate (MPA) after primary histological response. A multicentre
A Orbo et al.
Gynecologic oncology, 95(1), 82-88 (2004-09-24)
The purpose of the current study was to characterize the role of PTEN in malignant transformation and to evaluate the significance of mutated PTEN exons as prognostic markers in the carcinogenesis of endometrial hyperplasia. A comparison of PTEN mutations as
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service